Solvonis Therapeutics Broadens R&D Portfolio Through Awakn Life Sciences Acquisition

PUBLISHED: 28 May 2025 @ 18:02 | Comments (0) | More info about Fiona Craig

Solvonis Therapeutics plc (LSE:SVNS) has announced the successful acquisition of Awakn Life Sciences Corp., a move that significantly expands its research and development capabilities. This strategic acquisition strengthens Solvonis’ focus on addressing addiction and mental health conditions, particularly Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).

As part of the deal, Solvonis gains access to the investigational treatment SVNS-001, which is currently undergoing a Phase 3 clinical trial in the UK for severe AUD. The acquisition is expected to accelerate the company’s development timeline and bolster its position within the biopharmaceutical sector, targeting high-need therapeutic areas with limited existing solutions.

Company Snapshot: Solvonis Therapeutics plc

Headquartered in London, Solvonis Therapeutics is a clinical-stage biopharma company committed to advancing innovative therapies for neuropsychiatric disorders. Listed on the London Stock Exchange, the company is focused on repurposing and developing new drug candidates to treat conditions with substantial unmet medical needs, including AUD and PTSD.

Despite some financial headwinds, as indicated by a bearish technical sentiment, the company’s recent strategic expansion signals strong intent to capture market share in specialized mental health therapeutics.

Average Daily Trading Volume: 10,789,241
Technical Market Signal: Sell
Current Market Capitalization: £3.04 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Solvonis Therapeutics Raises £2 Million to Accelerate Mental Health Therapeutics Development by Fiona Craig